The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

Ju Hee Kang, Magdalena Korecka, Michal J. Figurski, Jon B. Toledo, Kaj Blennow, Henrik Zetterberg, Teresa Waligorska, Magdalena Brylska, Leona Fields, Nirali Shah, Holly Soares, Robert A. Dean, Hugo Vanderstichele, Ronald C. Petersen, Paul S. Aisen, Andrew J. Saykin, Michael W. Weiner, John Q. Trojanowski, Leslie M. Shaw

Research output: Contribution to journalReview article

31 Scopus citations


Introduction We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ<inf>1-42</inf>), t-tau, and p-tau<inf>181</inf> analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids. Methods Review publications authored or coauthored by ADNI Biomarker core faculty and selected non-ADNI studies to deepen the understanding and interpretation of CSF Aβ<inf>1-42</inf>, t-tau, and p-tau<inf>181</inf> data. Results CSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non-ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies. Discussion Further studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease-modifying therapeutic trials.

Original languageEnglish (US)
Pages (from-to)772-791
Number of pages20
JournalAlzheimer's and Dementia
Issue number7
StatePublished - Jul 1 2015


  • ADNI
  • Alzheimer's disease
  • Aβ<inf>1-42</inf>
  • Biomarkers
  • Cerebrospinal fluid
  • Disease-modifying therapy
  • Immunoassay
  • Mild cognitive impairment
  • Plasma
  • Tau

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Fingerprint Dive into the research topics of 'The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans'. Together they form a unique fingerprint.

  • Cite this

    Kang, J. H., Korecka, M., Figurski, M. J., Toledo, J. B., Blennow, K., Zetterberg, H., Waligorska, T., Brylska, M., Fields, L., Shah, N., Soares, H., Dean, R. A., Vanderstichele, H., Petersen, R. C., Aisen, P. S., Saykin, A. J., Weiner, M. W., Trojanowski, J. Q., & Shaw, L. M. (2015). The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 11(7), 772-791.